Terms: = Kidney tumors AND FGFR1, CEK, 2260, ENSG00000077782, P11362, FLT2, CD331, H3, HBGFR, FGFBR, H5, KAL2, H2, BFGFR, N-SAM, H4
252 results:
1. KMT2 Family of H3K4 Methyltransferases: Enzymatic Activity-dependent and -independent Functions.
Van HT; Xie G; Dong P; Liu Z; Ge K
J Mol Biol; 2024 Apr; 436(7):168453. PubMed ID: 38266981
[TBL] [Abstract] [Full Text] [Related]
2. Immunomodulatory response to neoadjuvant nivolumab in non-metastatic clear cell renal cell carcinoma.
Singla N; Nirschl TR; Obradovic AZ; Shenderov E; Lombardo K; Liu X; Pons A; Zarif JC; Rowe SP; Trock BJ; Hammers HJ; Bivalacqua TJ; Pierorazio PM; Deutsch JS; Lotan TL; Taube JM; Ged YMA; Gorin MA; Allaf ME; Drake CG
Sci Rep; 2024 Jan; 14(1):1458. PubMed ID: 38228729
[TBL] [Abstract] [Full Text] [Related]
3. Therapeutic Efficacy of YM155 to Regulate an Epigenetic Enzyme in Major Subtypes of RCC.
Hong SH; Lee YJ; Jang EB; Hwang HJ; Kim ES; Son DH; Park SY; Moon HS; Yoon YE
Int J Mol Sci; 2023 Dec; 25(1):. PubMed ID: 38203388
[TBL] [Abstract] [Full Text] [Related]
4. Conformationally constrained potent inhibitors for enhancer of zeste homolog 2 (EZH2).
Xu X; Chen J; Wang G; Zhang X; Li Q; Zhou X; Guo F; Li M
Bioorg Med Chem Lett; 2024 Jan; 97():129558. PubMed ID: 37956762
[TBL] [Abstract] [Full Text] [Related]
5. Comparison of second-line treatments in metastatic renal cell carcinoma patients: A single-center experience.
Pehlivan M; Paksoy N; Aydin E; Basaran M; Ekenel M
Medicine (Baltimore); 2023 Oct; 102(41):e35245. PubMed ID: 37832108
[TBL] [Abstract] [Full Text] [Related]
6. A novel drug specific mRNA biomarker predictor for selection of patients responding to dovitinib treatment of advanced renal cell carcinoma and other solid tumors.
Knudsen S; Hansen A; Foegh M; Petersen S; Mekonnen H; Jia L; Shah P; Martin V; Frykman G; Pili R
PLoS One; 2023; 18(8):e0290681. PubMed ID: 37647320
[TBL] [Abstract] [Full Text] [Related]
7. Knockdown of SETD2 promotes erastin-induced ferroptosis in ccRCC.
Xue W; Jian W; Meng Y; Wang T; Cai L; Yu Y; Yu Y; Xia Z; Zhang C
Cell Death Dis; 2023 Aug; 14(8):539. PubMed ID: 37604811
[TBL] [Abstract] [Full Text] [Related]
8. A role for SETD2 loss in tumorigenesis through DNA methylation dysregulation.
Javaid H; Barberis A; Chervova O; Nassiri I; Voloshin V; Sato Y; Ogawa S; Fairfax B; Buffa F; Humphrey TC
BMC Cancer; 2023 Aug; 23(1):721. PubMed ID: 37528416
[TBL] [Abstract] [Full Text] [Related]
9. SETD2 loss in renal epithelial cells drives epithelial-to-mesenchymal transition in a TGF-β-independent manner.
Wang T; Wagner RT; Hlady RA; Pan X; Zhao X; Kim S; Wang L; Lee JH; Luo H; Castle EP; Lake DF; Ho TH; Robertson KD
Mol Oncol; 2024 Jan; 18(1):44-61. PubMed ID: 37418588
[TBL] [Abstract] [Full Text] [Related]
10. Targeted Profiling of Epitranscriptomic Reader, Writer, and Eraser Proteins Regulated by H3K36me3.
Yin J; Qi TF; Li L; Wang Y
Anal Chem; 2023 Jun; 95(25):9672-9679. PubMed ID: 37296074
[TBL] [Abstract] [Full Text] [Related]
11. Extensive intratumor regional epigenetic heterogeneity in clear cell renal cell carcinoma targets kidney enhancers and is associated with poor outcome.
El Khoury LY; Pan X; Hlady RA; Wagner RT; Shaikh S; Wang L; Humphreys MR; Castle EP; Stanton ML; Ho TH; Robertson KD
Clin Epigenetics; 2023 Apr; 15(1):71. PubMed ID: 37120552
[TBL] [Abstract] [Full Text] [Related]
12. B7-H3 but not PD-L1 is involved in the antitumor effects of Dihydroartemisinin in non-small cell lung cancer.
Hu BQ; Huang JF; Niu K; Zhou J; Wang NN; Liu Y; Chen LW
Eur J Pharmacol; 2023 Jul; 950():175746. PubMed ID: 37105515
[TBL] [Abstract] [Full Text] [Related]
13. B7-H3 expression is associated with high PD-L1 expression in clear cell renal cell carcinoma and predicts poor prognosis.
Lee JH; Kim YJ; Ryu HW; Shin SW; Kim EJ; Shin SH; Park JY; Kim SY; Hwang CS; Na JY; Shin DH; Kim JY; Lee HJ
Diagn Pathol; 2023 Mar; 18(1):36. PubMed ID: 36894965
[TBL] [Abstract] [Full Text] [Related]
14. PBRM1 bromodomains associate with RNA to facilitate chromatin association.
De Silva SM; Dhiman A; Sood S; Mercedes KF; Simmons WJ; Henen MA; Vögeli B; Dykhuizen EC; Musselman CA
Nucleic Acids Res; 2023 May; 51(8):3631-3649. PubMed ID: 36808431
[TBL] [Abstract] [Full Text] [Related]
15. Renal Clearable Catalytic 2D Au-Porphyrin Coordination Polymer Augmented Photothermal-Gas Synergistic Cancer Therapy.
Zhou G; Chen Y; Chen W; Wu H; Yu Y; Sun C; Hu B; Liu Y
Small; 2023 Apr; 19(14):e2206749. PubMed ID: 36599631
[TBL] [Abstract] [Full Text] [Related]
16. The tumor microenvironment and immune targeting therapy in pediatric renal tumors.
Hont AB; Dumont B; Sutton KS; Anderson J; Kentsis A; Drost J; Hong AL; Verschuur A
Pediatr Blood Cancer; 2023 May; 70 Suppl 2():e30110. PubMed ID: 36451260
[TBL] [Abstract] [Full Text] [Related]
17. Ginsenoside Rg3 inhibits renal cell carcinoma cell migration, invasion, colony formation, and tube formation and enhances apoptosis through promoting the DNA demethylation and histone acetylation.
Ma Z; Zuo Y; Wang W
J Pharm Pharmacol; 2023 Jan; 75(1):76-86. PubMed ID: 36264186
[TBL] [Abstract] [Full Text] [Related]
18. Prognostic value of Talin-1 in renal cell carcinoma and its association with B7-H3.
Saeednejad Zanjani L; Vafaei S; Abolhasani M; Fattahi F; Madjd Z
Cancer Biomark; 2022; 35(3):269-292. PubMed ID: 36245369
[TBL] [Abstract] [Full Text] [Related]
19. Dirty necrosis in renal cell carcinoma is associated with NETosis and systemic inflammation.
Kuroe T; Watanabe R; Morisue R; Miyazaki S; Kojima M; Murata SC; Nakai T; Taki T; Sakashita S; Sakamoto N; Matsubara N; Masuda H; Ushiku T; Ishii G
Cancer Med; 2023 Feb; 12(4):4557-4567. PubMed ID: 36127822
[TBL] [Abstract] [Full Text] [Related]
20. Compound C Inhibits Renca Renal Epithelial Carcinoma Growth in Syngeneic Mouse Models by Blocking Cell Cycle Progression, Adhesion and Invasion.
Lee M; Ham NY; Hwang CY; Jang J; Lee B; Jeong JW; Kang I; Yeo EJ
Int J Mol Sci; 2022 Aug; 23(17):. PubMed ID: 36077072
[TBL] [Abstract] [Full Text] [Related]
[Next]
